(Q44074214)

29 November 2017

1 reference

title

Managing patients with hepatitis‑B-related or hepatitis‑C-related decompensated cirrhosis (English)

1 reference

29 November 2017

Scott A Fink

1

1 reference

29 November 2017

Ira M Jacobson

series ordinal

2

1 reference

29 November 2017

language of work or name

English

0 references

publication date

1 May 2011

1 reference

Nature Reviews Gastroenterology & Hepatology

29 November 2017

published in

1 reference

29 November 2017

volume

8

1 reference

29 November 2017

issue

5

1 reference

29 November 2017

page(s)

285-295

1 reference

Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Efficacy of interferon treatment for patients with chronic hepatitis C: comparison of response in cirrhotics, fibrotics, or nonfibrotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Peg-interferon alone or combined with ribavirin in HCV cirrhosis with portal hypertension: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Predictive value of on-treatment response during full-dose antiviral therapy of patients with hepatitis C virus cirrhosis and portal hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Antiviral therapy increases the risk of bacterial infections in HCV-infected cirrhotic patients awaiting liver transplantation: A retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Recurrent and new hepatitis C virus infection after liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Predictors of patient and graft survival following liver transplantation for hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Histological benefits of virological response to peginterferon alfa-2a monotherapy in patients with hepatitis C and advanced fibrosis or compensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Outcome of sustained virological responders with histologically advanced chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Predicting mortality risk in patients with compensated HCV-induced cirrhosis: a long-term prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Interferon reduces the risk of hepatocellular carcinoma in hepatitis C virus-related chronic hepatitis/liver cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Telaprevir for previously treated chronic HCV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Diagnosis, management, and treatment of hepatitis C: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

A prospective and comparative cohort study on efficacy and drug resistance during long-term lamivudine treatment for various stages of chronic hepatitis B and cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Adefovir dipivoxil is effective for the treatment of cirrhotic patients with lamivudine failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Hepatitis B virus load in serum does not reflect histologic activity in patients with decompensated cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Course of disease and survival after onset of decompensation in hepatitis B virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Adefovir dipivoxil for wait-listed and post–liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Liver Transplantation and Hepatitis C. Proceedings of a consensus development symposium

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Hepatocellular carcinoma in long-term sustained virological responders following antiviral combination therapy for chronic hepatitis C

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

EASL Clinical Practice Guidelines: management of chronic hepatitis B.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRGASTRO.2011.57

Chronic hepatitis B: update 2009

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21695841

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRGASTRO.2011.57

1 reference

release_npxquwsj35dqpijmlrlgbyjxsq

29 November 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/npxquwsj35dqpijmlrlgbyjxsq

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference